Professor, The Center for Biomedical Science, The Feinstein Institute for Medical Research
Director, Laboratory of Emergency Medicine, The Feinstein Institute for Medical Research
Professor of Emergency Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Phone: (516) 562-2823
Dr. Wang is currently the chief of the Basic Science Research Program in the Department of Emergency Medicine at North Shore University Hospital. He also serves as a professor of molecular medicine at the Elmezzi Graduate School, and the director of the Laboratory of Emergency Medicine at the Feinstein Institute for Medical Research.
He earned a BS degree in biology from Hebei University in 1984, and then completed an MS degree in microbiology at Zhejiang University in 1987. In 1992, Dr. Wang received his PhD in microbiology from Louisiana State University, and subsequently finished a three-year postdoctoral fellowship in cell biology at the University of North Carolina-Chapel Hill. In 1995, Dr. Wang joined the Department of Emergency Medicine at North Shore University Hospital as the chief of the Basic Science Research Program.
Since 2002, Dr. Wang has obtained several R01 grants from the National Institute of General Medical Science (R01GM063075 and R01GM070817) and the National Center of Complementary and Alternative Medicine (R01AT005076). He has procured several patents regarding the use of acute phase proteins (e.g., fetuin and serum amyloid A) and herbal components (such as tanshinone IIA) as a potential therapeutic targets and agents. Since 1995, Dr. Wang has published more than 150 research and review articles, which have been cited > 19,500 times by the Web of Science (h-index = 58) and > 29,500 times by Google Scholar (h-index = 68).
Dr. Wang currently serves as a referee for 40 journals, and editorial board member for five scientific journals (including Shock, Inflammation & Allergy – Drug target, SOJ Immunology, and Military Medical Research). Since 2009, he serves as a Reviewer / Member of multiple NIH Special Emphasis Panels. Dr. Wang also plays an active role in international conferences by serving as a co-moderator and invited speaker at several international shock and sepsis conferences.
He has not focused all of his energies solely on research, but has made significant contributions to academia and the advancement of knowledge to the future of biomedical research. Dr. Wang is currently mentoring postdoctoral fellows and high school students who have been named semifinalists in several international science competitions.
Dr. Wang’s laboratory has been closely collaborating with physicians of the North Shore University Hospital Emergency Medicine Department for more than 22 years. This joint venture allows him to ask clinically relevant scientific questions regarding the cause of human diseases (such as sepsis), thereby bringing new knowledge into diagnostic and therapeutic solutions for Emergency Department patients.
Severe sepsis is an overwhelming systemic inflammatory response to infection, claiming approximately 225,000 victims annually in the U.S. alone. Its high mortality is in part mediated by dysregulated inflammatory responses manifested by the excessive accumulation of various pro-inflammatory cytokines. To uncover the mechanisms underlying the pathogenesis of sepsis, Dr. Wang and his team have been attempting to identify novel therapeutic targets and/or agents for this disease since 1996. One outgrowth of this effort was the seminal discovery of a ubiquitous nucleosomal protein, HMGB1, as a critical late mediator of lethal endotoxemia (Science 1999, 285: 248-251). This groundbreaking finding laid down a foundation for further uncovering the intricate mechanisms of innate immune regulation, and stimulated an interest in developing novel therapeutic strategies for sepsis and other inflammatory diseases.
Dr. Wang is investigating the molecular mechanisms of HMGB1 release by identifying potential endogenous negative (inhibiting) and positive (stimulating) regulators. This line of investigation led to the discovery of several innate immune cell-derived pro-inflammatory cytokines (e.g., IFN-gamma), liver-derived acute phase proteins (such as fetuin-A and serum amyloid A), and cytoplasmic membrane-associated hemichannel molecules (e.g., connexin 43) as important HMGB1 regulators. Moving forward, we are investigating the intricate mechanisms by which these endogenous proteins regulate HMGB1 release, and influence the pathological outcomes in animal models of endotoxemia and sepsis.
Many Chinese herbs belong to the realm of complementary and alternative medicine, and have been traditionally used for treating various inflammatory diseases. To further elucidate mechanisms underlying the pathogenesis of sepsis, we have screened >50 commonly used medicinal herbs for potential HMGB1-inhibiting properties. Among them, the major components of several Chinese herbs including Danggui (Angelica sinensis), Danshen (Salvia miltiorrhiza), Green tea (Camellia sinensis) and Gancao (Radix glycyrrhizae) effectively attenuate HMGB1 release, and confer protection against lethal endotoxemia and sepsis. He is now uncovering the novel and distinct mechanisms by which various herbal ingredients block HMGB1 release at molecular and cellular levels. Moreover, He will also explore their therapeutic potential using various animal models of inflammatory diseases, with particular attempt to advance the efficacy from employing nanotechnology and other chemical strategies.
In summary, the investigation of novel inflammatory mediators and their inhibitors will shed light on the mechanisms underlying regulation of the innate immune response, and provide clues to the development of novel therapeutics for human sepsis.
Shu Zhu, MD, PhD
Research: Investigating innate immune modulatory mechanisms of Chinese herbal medicine.
Phone: (516) 562-2144
Weiqiang Chen, MD, PhD
Phone: (516) 562-2144
Yongjun Wang, MD, PhD
Research: Investigating mechanisms underlying regulation of HMGB1 release or cytokine activities.
Phone: (516) 562-1467
Lynn X. Qiang, MD, PhD
Research: Investigating the role of dermcidin in sterile and infectious inflammation.
Phone: (516) 562-2016
Hebei University, P. R. China
Field of Study: Biology
Zhejiang University, P. R. China
Field of Study: Microbiology
Louisiana State University, Baton Rouge, LA
Field of Study: Microbiology
University of North Carolina at Chapel Hill, NC
Field of Study: Cell Biology
2016-2022 Member, NIH/NIGMS, The Surgery, Anesthesiology and Trauma (SAT) Study Section
2016 Member, NIH/NIGMS ZRG1 SBIB-P (50) Special Emphasis Panel, RFA-TW-16-001 Fogarty Global Injury and Trauma Research Program (D43)
2015 Member, NIH/NIGMS ZRG1 F15-P(20) Fellowship Special Review Panel, Surgical Sciences, Biomedical Imaging and Bioengineering
2015 Member, NIH/NIGMS ZRG1SBIB Z02 Special Emphasis Panel, “Member Conflict: Surgical Sciences and Bioengineering”
2014-2016 Ad hoc grant reviewer, Health and Medical Research Fund, Food and Health Bureau,The Government of the Hong Kong Special Administrative Region, P.R. China
2014-2015 Member, NIH/NIGMS ZRG1SBIB V02 Special Emphasis Panel, “Member Conflict: Surgical Sciences and Bioengineering”
2014-2015 Ad hoc Reviewer, the Surgery (SURG) review panel, the U.S. Department of Veterans Affairs
2013-2016 Ad hoc Reviewer, NIH/NIGMS, the Surgery, Anesthesiology and Trauma (SAT) Study Section
2013 Member, NIH/NIDDK ZDK1 GRB-D(J1) Special Review Panel, “Small R03 Grants for New Investigators to Promote Diversity”
2012-2015 Peking Union Scholar Chair Professor, Chinese Academy of Medical Sciences & Peking Union Medical College
2010 Faculty Research Award, The Feinstein Institute for Medical Research
2009 Faculty Research Award, The Feinstein Institute for Medical Research
2006 Faculty Research Award, The Feinstein Institute for Medical Research
2004 Faculty Research Award,Northwell Health Research Institute
2003 Faculty Research Award, Northwell Health Research Institute